Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

SAB Biotherapeutics, Inc. - Common Stock (NQ:SABS)

1.790 +0.070 (+4.07%)
Streaming Delayed Price Updated: 3:56 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023
SAB Biotherapeutics' (NASDAQ: SABS) Q3 net loss reached $(7.1) million, equivalent to an EPS loss of $(0.16), as compared to a net loss of $(4.1) million a year ago. Cash and cash equivalents were $8.3... 
Via Benzinga
SAB Biotherapeutics Unveils New Data From COVID-19 Programs Reinforcing Efficacy Against Variants
Via Benzinga
SAB Biotherapeutics Shifts Focus On Infection Candidate As DoD Contract Closes
Via Benzinga
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
SAB highlights data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19, showing broad efficacy against highly mutating viruses associated with respiratory disease 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Says Influenza, COVID-19 Candidates Showing Broad Efficacy Against Variants
SAB Biotherapeutics Inc (NASDAQ: SABS) presented an overview of its DiversitAb polyclonal platform at the 2022 Plasma Product Biotechnology Conference. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
Why Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From Yesterday
Gainers Chardan NexTech Acquisition 2 Corp. (NASDAQ: CNTQ) shares surged 102.6% to close at $21.54 on Wednesday. 
Via Benzinga
Why Sotera Health Shares Are Trading Lower By Around 13%, Here Are 38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Pineapple Energy Inc. (NASDAQ: PEGY) shares jumped 104% to $2.9201. Shares of this low-float penny stock closed up about 80% on Tuesday. 
Via Benzinga
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bionano Genomics (NASDAQ:BNGO) stock increased by 9.8% to $2.24. The company's market cap stands at $649.9 million. 
Via Benzinga
SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron
SAB’s fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Gainers 
Via Benzinga
SAB Biotherapeutics And 1 Other Stock Under $1 Insiders Are Aggressively Buying
The Nasdaq 100 gained by more than 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
  
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) shares rose 141.5% to $5.46 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 114.7... 
Via Benzinga
51 Biggest Movers From Yesterday
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are... 
Via Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 139% to $5.40 after the company announced that two of its designed mRNA molecules are effective at destroying... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Longeveron (NASDAQ:LGVN) stock rose 60.6% to $10.79 during Thursday's regular session. As of 13:31 EST, this security is trading at a volume of 84.1 million... 
Via Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 71% to $11.57 after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.